TY - BOOK ID - 218732 TI - Leading pharmaceutical innovation : trends and drivers for growth in the pharmaceutical industry AU - Gassmann, Oliver AU - Reepmeyer, Gerrit AU - Zedtwitz, Maximilian von PY - 2008 SN - 1281231746 9786611231743 3540776362 3540776354 3642096387 PB - Berlin : Springer, DB - UniCat KW - Pharmaceutical industry KW - Drugs KW - Technological innovations. KW - Technological innovations KW - Research KW - Management. KW - Management KW - Medicaments KW - Medications KW - Medicine (Drugs) KW - Medicines (Drugs) KW - Pharmaceuticals KW - Prescription drugs KW - Bioactive compounds KW - Medical supplies KW - Pharmacopoeias KW - Chemotherapy KW - Materia medica KW - Pharmacology KW - Pharmacy KW - Drug industry KW - Drug trade KW - Medicine industry KW - Medicines industry KW - Prescription medicine industry KW - Chemical industry KW - Medical innovations KW - Economic policy. KW - Pharmacy. KW - Innovation/Technology Management. KW - R & D/Technology Policy. KW - Public Health. KW - Chemistry KW - Medicine KW - Economic nationalism KW - Economic planning KW - National planning KW - State planning KW - Economics KW - Planning KW - National security KW - Social policy KW - Administration KW - Industrial relations KW - Organization KW - Industrial management. KW - Public health. KW - Community health KW - Health services KW - Hygiene, Public KW - Hygiene, Social KW - Public health services KW - Public hygiene KW - Social hygiene KW - Health KW - Human services KW - Biosecurity KW - Health literacy KW - Medicine, Preventive KW - National health services KW - Sanitation KW - Business administration KW - Business enterprises KW - Business management KW - Corporate management KW - Corporations KW - Industrial administration KW - Management, Industrial KW - Rationalization of industry KW - Scientific management KW - Business KW - Industrial organization UR - https://www.unicat.be/uniCat?func=search&query=sysid:218732 AB - Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. Our findings are illustrated by cases from Europe, the US, and Asia. "One way we try to foster innovation - both the technological innovation and the organizational innovation - is to align our business objectives with our ideals." Dr. Daniel Vasella, CEO, Novartis International "Pharmaceutical innovation is in crisis. The industry will have to change both its innovation processes and its business models in order to reverse these trends and prosper in the future. Professors Gassmann, Reepmeyer and von Zedtwitz have marshalled together an impressive array of research in one volume. This book should prove to be an indispensable resource for all participants in the pharmaceutical industry." Prof. Henry Chesbrough, Executive Director, Center for Open Innovation, Haas School of Business, University of California, Berkeley "It´s time for a paradigm shift in pharmaceutical R&D. This book will tell you why." Dr. Goetz Baumann, Business Unit Manager, Hoffmann-La Roche (Germany) "This book offers a fact based, comprehensive insight to the increasing challenges of today`s drug development. Well worth reading not just for newcomers to the industry but also for industry professionals who want to understand the big picture". Dr. Pius Renner, Head of Strategic Planning and Portfolio Management in Development, Novartis Pharma . ER -